Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 1
2010 2
2011 2
2012 2
2014 1
2015 3
2016 1
2017 1
2018 3
2019 1
2020 6
2021 8
2022 9
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 2
Small-molecule antiviral treatments for COVID-19: A systematic review and network meta-analysis.
Zheng B, Zhao Q, Yang W, Feng P, Xin C, Ying Y, Yang B, Han B, Zhu J, Zhang M, Li G. Zheng B, et al. Int J Antimicrob Agents. 2024 Mar;63(3):107096. doi: 10.1016/j.ijantimicag.2024.107096. Epub 2024 Jan 18. Int J Antimicrob Agents. 2024. PMID: 38244811 Free article. Review.
In patients with mild-to-moderate COVID-19, proxalutamide exhibited the above advantages, except for mortality reduction. Triazavirin was the most effective treatment for reducing the time required for viral clearance and improving the discharge rate. ...CONCLUSIONS: A tho …
In patients with mild-to-moderate COVID-19, proxalutamide exhibited the above advantages, except for mortality reduction. Triazavirin …
Preparation of chitosan-coated liposomes as a novel carrier system for the antiviral drug Triazavirin.
Kozhikhova KV, Ivantsova MN, Tokareva MI, Shulepov ID, Tretiyakov AV, Shaidarov LV, Rusinov VL, Mironov MA. Kozhikhova KV, et al. Pharm Dev Technol. 2018 Apr;23(4):334-342. doi: 10.1080/10837450.2016.1242624. Epub 2016 Oct 25. Pharm Dev Technol. 2018. PMID: 27681534
The prepared liposomes were loaded with the novel antiviral drug Triazavirin and used to determine the release profile. Triazavirin was included into liposome layer as a salt with biocompatible choline derivatives of limiting fatty acids. ...
The prepared liposomes were loaded with the novel antiviral drug Triazavirin and used to determine the release profile. Triazaviri …
[A new approach to etiotropic therapy ARVI in children].
Sabitov AU, Kovtun OP, Esaulenko EV, Sorokin PV. Sabitov AU, et al. Ter Arkh. 2022 Dec 26;94(11):1278-1284. doi: 10.26442/00403660.2022.11.201979. Ter Arkh. 2022. PMID: 37167166 Russian.
AIM: Confirmation of the efficacy and safety of the drug riamilovir (Triazavirin()), 100 mg capsules, in children aged 12-17 years with the diagnosis of acute viral respiratory infection (ARVI). ...RESULTS: As a result of a clinical study, the efficacy and safety of …
AIM: Confirmation of the efficacy and safety of the drug riamilovir (Triazavirin()), 100 mg capsules, in children aged 12-17 y …
[Investigation of Triazavirin antiviral activity against tick-borne encephalitis pathogen in cell culture].
Loginova SIa, Borisevich SV, Rusinov VL, Ulomskiĭ UN, Charushin VN, Chupakhin ON. Loginova SIa, et al. Antibiot Khimioter. 2014;59(1-2):3-5. Antibiot Khimioter. 2014. PMID: 25051708 Russian.
The efficacy of Triazavirin against the tick-borne encephalitis virus was estimated in the sensitive cell culture vs. the active drug Ribavirin. In a concentration of 128 mcg/ml Triazavirin was shown active in inhibition of the tick-borne encephalitis virus reproduc …
The efficacy of Triazavirin against the tick-borne encephalitis virus was estimated in the sensitive cell culture vs. the active drug …
[A new antiviral drug Triazavirin: results of phase II clinical trial].
Kiselev OI, Deeva EG, Mel'nikova TI, Kozeletskaia KN, Kiselev AS, Rusinov VL, Charushin VN, Chupakhin ON. Kiselev OI, et al. Vopr Virusol. 2012 Nov-Dec;57(6):9-12. Vopr Virusol. 2012. PMID: 23477247 Clinical Trial. Russian.
The results of the clinical trial testing the efficacy of a new anti-influenza drug Triazavirin are presented in this work. The data of the trial were gathered during the 2010 influenza season. ...The re-isolation rate of the influenza A and B viruses was significantly low …
The results of the clinical trial testing the efficacy of a new anti-influenza drug Triazavirin are presented in this work. The data …
[Therapeutic efficacy of Triazavirin, a novel Russian chemotherapeutic, against influenza virus A (H5N1)].
Loginova SIa, Borisevich SV, Maksimov VA, Bondarev VP, Kotovskaia SK, Rusinov VL, Charushin VN, Chupakhin ON. Loginova SIa, et al. Antibiot Khimioter. 2011;56(1-2):10-2. Antibiot Khimioter. 2011. PMID: 21780665 Russian.
Therapeutic activity of Triazavirin against experimental influenza A was studied on albino mice intranazally infected with influenza virus A/Chicken/Kurgan/Russia/02/05 (H5N1) vs. reference drugs (Oseltamivir, Remantadin and Arbidol). ...During the whole observation period …
Therapeutic activity of Triazavirin against experimental influenza A was studied on albino mice intranazally infected with influenza …
[Investigation of Therapeutic Efficacy of Triazavirin Against Experimental Forest-Spring Encephalitis on Albino Mice].
Loginova SY, Borisevich SV, Rusinov VL, Ulomsky EN, Charushin VN, Chupakhin ON, Sorokin PV. Loginova SY, et al. Antibiot Khimioter. 2015;60(7-8):11-3. Antibiot Khimioter. 2015. PMID: 26863736 Russian.
The comparative study of the therapeutic efficacy of Triazavirin against experimental Forest-Spring encephalitis on albino mice vs. the active drug Ribavirin showed that in high doses (200-400 mg/kg) Triazavirin moderately protected the infected animals. ...
The comparative study of the therapeutic efficacy of Triazavirin against experimental Forest-Spring encephalitis on albino mice vs. t …
Antiplatelet Activity of Riamilovir under Conditions of Lipopolysaccharide Intoxication.
Spasov AA, Kucheryavenko AF, Sirotenko VS, Gaidukova KA, Uskov GM. Spasov AA, et al. Bull Exp Biol Med. 2022 May;173(1):41-45. doi: 10.1007/s10517-022-05489-0. Epub 2022 May 26. Bull Exp Biol Med. 2022. PMID: 35616790 Free PMC article.
We studied the effect of antiviral agent riamilovir on ADP-induced platelet aggregation in the absence and presence of LPS. ...In in vivo experiments, riamilovir under conditions of hypercytokinemia blocked platelet aggregation in rats by 64%....
We studied the effect of antiviral agent riamilovir on ADP-induced platelet aggregation in the absence and presence of LPS. ...In in …
41 results

Searches related to "triazavirin"